Apyx Medical Corp reported the first quarter ended March 31, 2026 results: revenue total revenue of $12.5 million, net income Net loss attributable to stockholders of $2.1 million, EPS $0.05 per share. Guidance raised.
“99.1) --- EX-99.1 2 ex_905122.htm EXHIBIT 99.1 ex_905122.htm EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2026 Financial Results • Reported total revenue of $12.5 million in the first quarter of 2026 primarily driven by 36% growth in the Surgical Aesthetics segment • Raised total revenue guidance for FY2026 to a range of $59.0 million to $60.0”
Governance Changes
Apyx Medical Corp: Removed Article EIGHTH from Certificate of Incorporation and replaced with 'intentionally omitted' (effective 2025-12-08).
“On December 8, 2025, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Amendment.”
Shawn Roman was appointed as Chief Operating Officer at Apyx Medical Corp.
“following the prior announcement that it had appointed Shawn Roman as its Chief Operating Officer”
Shawn D. Roman was appointed as Chief Operating Officer at Apyx Medical Corp.
“On November 6, 2024, the Board appointed Shawn D. Roman as the Chief Operating Officer of the Company, effective immediately.”
Craig Swandal resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
Michael Geraghty resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
John Andres resigned as Director at Apyx Medical Corp.
“On November 4, 2024, John Andres, Michael Geraghty, and Craig Swandal resigned from the Board of Directors, with such resignations effective immediately.”
Earnings Releases
Apyx Medical Corp reported year ending December 31, 2024 results: revenue $49.7 million to $52.9 million. Guidance reaffirmed.
“respectively . Full Year 2024 Financial Outlook: The Company is reaffirming its financial guidance for the year ending December 31, 2024: • Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December”
Earnings Releases
Apyx Medical Corp reported first quarter ended March 31, 2024 results: revenue $10.2 million, net income $7.6 million, EPS $0.22 per share. Guidance reaffirmed.
“quarter ended March 31, 2024; and reaffirmed its financial expectations for the full year ending December 31, 2024 First Quarter 2024 Financial Summary : • Total revenue of $10.2 million, a decrease of 16% year-over-year. ◦ Advanced Energy revenue of $7.5 million, a decrease of 23% year-over-year. ◦ OEM revenue of $2.8 million, an increase of 14% year-over-year.”
Stavros Vizirgianakis was appointed as Director and Chairman of the Board at Apyx Medical Corp.
“On May 7, 2024, the Board appointed Mr. Vizirgianakis to serve as a director and Chairman of the Board, to fill the vacancy created by the retirement of Andrew Makrides.”
Andrew Makrides retired as Chairman of the Board at Apyx Medical Corp.
“On May 7, 2024, Andrew Makrides announced his retirement as a director and Chairman of the Board, effective on the same date.”
Earnings Releases
Apyx Medical Corp reported year ended December 31, 2023 results: revenue $52.3 million, net income Net loss attributable to stockholders of $18.7 million. Guidance initiated.
“or 59%, year-over-year. • Adjusted EBITDA loss of $4.7 million, an increase of $0.6 million, or 14%, year-over-year. Full Year 2023 Financial Summary : • Total revenue of $52.3 million, an increase of 18% year-over-year. ◦ Advanced Energy revenue of $43.4 million, an increase of 18% year-over-year. ◦ OEM revenue of $9.0 million, an increase of 16%”
Earnings Releases
Apyx Medical Corp reported three months ended December 31, 2023 results: revenue $14.7 million, net income Net loss attributable to stockholders of $9.6 million.
“full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024. Fourth Quarter 2023 Financial Summary : • Total revenue of $14.7 million, an increase of 16% year-over-year. ◦ Advanced Energy revenue of $12.1 million, an increase of 15% year-over-year. ◦ OEM revenue of $2.5 million, an increase of 22%”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.